Results 101 to 110 of about 1,588,451 (244)
Vurdering av tester for PD-L1 ved urotelialt karsinom: en forenklet metodevurdering [PDF]
Hovedbudskap: Programmed cell death ligand 1 (PD-L1) på tumorceller kan binde til Programmed cell death protein 1 på immunceller og hindre disse i å bekjempe og nøytralisere kreftsvulster.
Brurberg, Kjetil Gundro +2 more
core
A novel PLGA/PBAE polymer microparticle platform revolutionizes intermediate‐stage liver cancer treatment by co‐delivering panobinostat and IL‐12 via a single TACE‐like injection. This sustained‐release system overcomes tumor immunosuppression, triggers robust innate and adaptive immune responses, and establishes tertiary lymphoid structures ...
Hongzhe Yu +7 more
wiley +1 more source
In Situ Visualization of PD-L1-Specific Glycosylation on Tissue Sections
Immune checkpoint therapy has provided a weapon against cancer, but its response rate has been extremely low due to the lack of effective predictors.
Mengjiao Huang (2623792) +21 more
core +1 more source
A Transformer‐based AI framework, DLINP, screens millions of compounds to identify Co68, a cobalt‐pincer organometallic complex that biases TLR4‐MD2 signaling toward antitumor interferon activation while suppressing inflammatory toxicity through an early TLR4‐SYK‐STAT1 axis.
Xuefei Guo +10 more
wiley +1 more source
This study identifies MZF1 as a core regulator of colon cancer via SnoN‐mediated TGF‐β suppression, proposes 10Panx Acetate as a targeted inhibitor, and validates MZF1/SnoN as prognostic markers for aggressive disease. ABSTRACT Colon cancer progression is associated with transcriptional and signaling abnormalities.
Siqi Sheng +9 more
wiley +1 more source
Purpose: Eyelid sebaceous gland carcinoma (SGC) is an aggressive but rare malignancy of ocular region. Over-expression of PD-L1 and PD-1 has been demonstrated in a variety of solid tumors including conjunctival melanoma.
Perumal Jayaraj, Seema Sen
doaj +1 more source
Circulating tumour cell PD-L1 test for head and neck cancers
Immune checkpoint inhibitors have gained traction over the last few years in the treatment of metastatic/recurrent head and neck squamous cell carcinoma (HNSCC) patients.
Chamindie Punyadeera +5 more
core +1 more source
Potential of Nanoparticle‐Based Phototherapies for Future Treatment of Uveal Melanoma
This review evaluates nanoparticle‐based phototherapies for uveal melanoma, highlighting emerging strategies to enhance tumor targeting, light delivery, and treatment precision. Preclinical data indicate improved efficacy and reduced toxicity, supporting their potential to enhance localized treatment and future translational advances. (Generated by the
Emilie Lambert +8 more
wiley +1 more source
BNC2 exhibits context‐dependent opposing functions across multiple cancer types. This study reveals BNC2 as an oncogenic driver of melanoma proliferation and metastasis through transcriptional activation of PIK3CA. The natural compound TSN simultaneously degrades BNC2 and its oncogenic partner SMAD3 via CRBN‐dependent ubiquitination.
Hui Dai +7 more
wiley +1 more source
Exosomal PD-L1 in cancer and other fields: recent advances and perspectives
PD-1/PD-L1 signaling is a key factor of local immunosuppression in the tumor microenvironment. Immune checkpoint inhibitors targeting PD-1/PD-L1 signaling have achieved tremendous success in clinic.
Man-Man Lu, Yu Yang
doaj +1 more source

